Iradimed (NASDAQ:IRMD) Updates Q1 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD) updated its first quarter 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 0.390-0.430 for the period, compared to the consensus earnings per share estimate of 0.410. The company issued revenue guidance of $19.2 million-$19.4 million, compared to the consensus revenue estimate of $19.1 million. Iradimed also updated its FY 2025 guidance to 1.710-1.810 EPS.

Analysts Set New Price Targets

Separately, StockNews.com lowered Iradimed from a “strong-buy” rating to a “buy” rating in a report on Thursday.

Iradimed Stock Performance

NASDAQ:IRMD traded down $4.58 during trading hours on Thursday, reaching $55.90. The company’s stock had a trading volume of 69,002 shares, compared to its average volume of 40,757. The company has a market capitalization of $708.25 million, a P/E ratio of 38.33 and a beta of 0.82. Iradimed has a 12 month low of $40.18 and a 12 month high of $63.29. The stock has a 50 day moving average price of $57.16 and a two-hundred day moving average price of $52.02.

Iradimed (NASDAQ:IRMD) last issued its quarterly earnings results on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.05). Iradimed had a return on equity of 23.99% and a net margin of 26.12%. As a group, analysts predict that Iradimed will post 1.52 EPS for the current fiscal year.

Insider Activity at Iradimed

In related news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at $237,470.94. This represents a 36.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 37.10% of the stock is owned by insiders.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.